Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
Cascone, T; William, WN; Weissferdt, A; Leung, CH; Lin, HY; Pataer, A; Godoy, MCB; Carter, BW; Federico, L; Reuben, A; Khan, MAW; Dejima, H; Francisco-Cruz, A; Parra, ER; Solis, LM; Fujimoto, J; Tran, HT; Kalhor, N; Fossella, FV; Mott, FE; Tsao, AS; Blumenschein, G; Le, XN; Zhang, JJ; Skoulidis, F; Kurie, JM; Altan, M; Lu, C; Glisson, BS; Byers, LA; Elamin, YY; Mehran, RJ; Rice, DC; Walsh, GL; Hofstetter, WL; Roth, JA; Antonoff, MB; Kadara, H; Haymaker, C; Bernatchez, C; Ajami, NJ; Jenq, RR; Sharma, P; Allison, JP; Futreal, A; Wargo, JA; Wistuba, II; Swisher, SG; Lee, JJ; Gibbons, DL; Vaporciyan, AA; Heymach, JV; Sepesi, B
Cascone, T (corresponding author), Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
NATURE MEDICINE, 2021; 27 (3): 504
